Global Monoclonal Antibody for Multiple Myeloma Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Elotuzumab
  • 1.4.3 Daratumumab
  • 1.4.4 Siltuximab
  • 1.4.5 Dacetuzumab
  • 1.4.6 Rituximab
  • 1.4.7 Other
• 1.5 Market by Application
  • 1.5.1 Global Monoclonal Antibody for Multiple Myeloma Market Share by Application (2014-2025)
  • 1.5.2 Hospital
  • 1.5.3 Drug Center
  • 1.5.4 Clinic
  • 1.5.5 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Monoclonal Antibody for Multiple Myeloma Market Size
• 2.2 Monoclonal Antibody for Multiple Myeloma Growth Trends by Regions
  • 2.2.1 Monoclonal Antibody for Multiple Myeloma Market Size by Regions (2014-2025)
  • 2.2.2 Monoclonal Antibody for Multiple Myeloma Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Monoclonal Antibody for Multiple Myeloma Market Size by by Players
  • 3.1.1 Global Monoclonal Antibody for Multiple Myeloma Revenue by by Players (2014-2019)
  • 3.1.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
• 3.2 Monoclonal Antibody for Multiple Myeloma Key Players Head office and Area Served
• 3.3 Key Players Monoclonal Antibody for Multiple Myeloma Product/Solution/Service
• 3.4 Date of Enter into Monoclonal Antibody for Multiple Myeloma Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Monoclonal Antibody for Multiple Myeloma Market Size by Type (2014-2019)
• 4.2 Global Monoclonal Antibody for Multiple Myeloma Market Size by Application (2014-2019)

5 United States

• 5.1 United States Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 5.2 Monoclonal Antibody for Multiple Myeloma Key Players in United States
• 5.3 United States Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 5.4 United States Monoclonal Antibody for Multiple Myeloma Market Size by Application

6 Europe

• 6.1 Europe Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 6.2 Monoclonal Antibody for Multiple Myeloma Key Players in Europe
• 6.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 6.4 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Application

7 China

• 7.1 China Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 7.2 Monoclonal Antibody for Multiple Myeloma Key Players in China
• 7.3 China Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 7.4 China Monoclonal Antibody for Multiple Myeloma Market Size by Application

8 Japan

• 8.1 Japan Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 8.2 Monoclonal Antibody for Multiple Myeloma Key Players in Japan
• 8.3 Japan Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 8.4 Japan Monoclonal Antibody for Multiple Myeloma Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 9.2 Monoclonal Antibody for Multiple Myeloma Key Players in Southeast Asia
• 9.3 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 9.4 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size by Application

10 India

• 10.1 India Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 10.2 Monoclonal Antibody for Multiple Myeloma Key Players in India
• 10.3 India Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 10.4 India Monoclonal Antibody for Multiple Myeloma Market Size by Application

11 Central & South America

• 11.1 Central & South America Monoclonal Antibody for Multiple Myeloma Market Size (2014-2019)
• 11.2 Monoclonal Antibody for Multiple Myeloma Key Players in Central & South America
• 11.3 Central & South America Monoclonal Antibody for Multiple Myeloma Market Size by Type
• 11.4 Central & South America Monoclonal Antibody for Multiple Myeloma Market Size by Application

12 International Players Profiles

• 12.1 Bristol Myers Squibb
  • 12.1.1 Bristol Myers Squibb Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.1.4 Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.1.5 Bristol Myers Squibb Recent Development
• 12.2 Abbvie
  • 12.2.1 Abbvie Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.2.4 Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.2.5 Abbvie Recent Development
• 12.3 Janssen Biotech
  • 12.3.1 Janssen Biotech Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.3.4 Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.3.5 Janssen Biotech Recent Development
• 12.4 Karyopharm Therapeutics
  • 12.4.1 Karyopharm Therapeutics Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.4.4 Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.4.5 Karyopharm Therapeutics Recent Development
• 12.5 PDL BioPharma
  • 12.5.1 PDL BioPharma Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.5.4 PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.5.5 PDL BioPharma Recent Development
• 12.6 Roche
  • 12.6.1 Roche Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.6.4 Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.6.5 Roche Recent Development
• 12.7 Seattle Genetics
  • 12.7.1 Seattle Genetics Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Monoclonal Antibody for Multiple Myeloma Introduction
  • 12.7.4 Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2014-2019)
  • 12.7.5 Seattle Genetics Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer